Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 … 11 12 13 14 15 … 47 Next »

Otezla and Palmoplantar psoriasis

Threaded Mode
Otezla and Palmoplantar psoriasis
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 54,276
Threads: 3,449
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 1
Psoriatic Arthritis Score: 2
PQOLS: 2
Treatment: Ilumetri / Coconut Oil
#1
News  Sat-21-10-2017, 15:40 PM
This study looked at the efficacy and impact on quality of life and work productivity of Otezla (apremilast) for the treatment of palmoplantar psoriasis.

Quote:
Background:
Palmoplantar psoriasis is a variant of psoriasis vulgaris which can severely impair quality of life.

Objectives:
The main objectives of this double-blind, placebo-controlled, randomized study were to assess the efficacy and impact on quality of life and work productivity of apremilast for the treatment of moderate to severe palmoplantar psoriasis.

Methods:
A total of 100 patients with moderate to severe palmoplantar psoriasis were randomized to either apremilast 30mg bid or placebo for 16 weeks. At Week 16, all patients received apremilast 30mg bid until Week 32. The primary endpoint was the proportion of patients who achieved a Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0/1 at Week 16.

Results:
There was no significant difference in the proportion of patients who achieved a PPPGA of 0/1 at Week 16 between patients randomized to apremilast (14%) and placebo (4%; p=0.1595). After 32 weeks of treatment with apremilast, 24% of patients achieved a PPGA of 0/1. In addition, apremilast was superior to placebo in achieving Palmoplantar Psoriasis Area Severity Index (PPPASI) 75 (apremilast: 22%; placebo: 8%; p=0.0499), in improving PPPASI (apremilast: -7.4±7.1; placebo: -3.6±5.9; p=0.0167), Dermatology Life Quality Index score (apremilast: -4.3±5.1; placebo: -0.8±4.5; p=0.0004), and in reducing activity impairment (apremilast: -11.0±22.3; placebo: 2.5±25.5; p=0.0063).

Conclusion:
Despite the absence of a significant difference between apremilast and placebo in proportion of patients achieving a PPPGA of 0/1, the presence of significant differences observed for several secondary endpoints suggest that apremilast may have a role in the treatment of moderate to severe palmoplantar psoriasis.

Source: onlinelibrary.wiley.com

*Early view funding unknown.

Otezla
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Otezla phase 3 study in moderate to severe genital psoriasis Fred 3 735 Wed-08-12-2021, 02:26 AM
Last Post: KatT
News Palmoplantar psoriasis flare-up after covid vaccination Fred 1 526 Mon-26-07-2021, 01:06 AM
Last Post: jiml
News Otezla effectiveness and safety study Fred 0 555 Wed-26-05-2021, 12:43 PM
Last Post: Fred
News Otezla phase 3 advance trial results Fred 0 513 Sat-24-04-2021, 11:30 AM
Last Post: Fred
News Otezla effectiveness, safety, and drug survival study Fred 0 793 Fri-10-04-2020, 12:27 PM
Last Post: Fred



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2022 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB
Linear Mode
Threaded Mode